RÉSUMÉ
The skin is the largest organ in the human body, and due to its barrier function, it is susceptible to multiple injuries. The appearance of infections during the wound healing process is a complication that represents a formidable hospital challenge. The presence of opportunistic bacteria with sophisticated resistance mechanisms is difficult to eradicate and compromises patients' lives. Therefore, the search for new efficacious treatments from natural sources that prevent and counteract infections, in addition to promoting the healing process, has increased in recent years. In this respect, films with the capability to protect wounds and release drugs are the presentation that predominates commercially in the hospital environment. Those films can offer several mechanical advantages such as physical protection to prevent opportunistic bacteria's entry, regulation of gas exchange, and capture of exudate through a swelling process. Wound dressings are generally curative materials easily adaptable to different anatomical regions, with high strength and elasticity, and some are even bioabsorbable. Additionally, the components of the films can actively participate in promoting the healing process. Even more, the film can be made up of carriers with other active participants to prevent and eradicate infections. Therefore, the extensive versatility, practicality, and usefulness of films from natural sources to address infectious processes during wound healing are relevant and recurrent themes. This work presents an analysis of the state-of-the-art of films with natural products focused on preventing and eradicating infections in wound healing.
Sujet(s)
Produits biologiques/pharmacologie , Infections opportunistes/prévention et contrôle , Cicatrisation de plaie/effets des médicaments et des substances chimiques , Infection de plaie/prévention et contrôle , Plaies et blessures/prévention et contrôle , Produits biologiques/composition chimique , Humains , Hydrogels/composition chimique , Hydrogels/pharmacologie , Membrane artificielle , Infections opportunistes/microbiologie , Plastifiants/composition chimique , Plastifiants/pharmacologie , Agents protecteurs/composition chimique , Agents protecteurs/pharmacologie , Infection de plaie/microbiologie , Plaies et blessures/microbiologieRÉSUMÉ
Vaccine-preventable infections (VPIs) are a common and serious complication following transplantation. One in six pediatric solid organ transplant recipients is hospitalized with a VPI in the first 5 years following transplant and these hospitalizations result in significant morbidity, mortality, graft injury, and cost. Immunizations are a minimally invasive, cost-effective approach to reducing the incidence of VPIs. Despite published recommendations for transplant candidates to receive all age-appropriate immunizations, under-immunization remains a significant problem, with the majority of transplant recipients not up-to-date on age-appropriate immunizations at the time of transplant. This is extremely concerning as the rate for non-medical vaccine exemptions in the United States (US) is increasing, decreasing the reliability of herd immunity to protect patients undergoing transplant from VPIs. There is an urgent need to better understand barriers to vaccinating this population of high-risk children and to develop effective interventions to overcome these barriers and improve immunization rates. Strengthened national policies requiring complete age-appropriate immunization for non-emergent transplant candidates, along with improved multi-disciplinary immunization practices and tools to facilitate and ensure complete immunization delivery to this high-risk population, are needed to ensure that we do everything possible to prevent infectious complications in pediatric transplant recipients.
Sujet(s)
Sujet immunodéprimé , Immunosuppresseurs/usage thérapeutique , Infections opportunistes/prévention et contrôle , Transplantation d'organe/tendances , Pédiatrie/tendances , Vaccination/tendances , Maladies évitables par la vaccination/prévention et contrôle , Facteurs âges , Humains , Immunosuppresseurs/effets indésirables , Incidence , Infections opportunistes/épidémiologie , Infections opportunistes/immunologie , Transplantation d'organe/effets indésirables , Appréciation des risques , Facteurs de risque , Maladies évitables par la vaccination/épidémiologie , Maladies évitables par la vaccination/immunologieRÉSUMÉ
The use of biological therapies has meant a great improvement in the management of several conditions like autoimmune, neoplastic or others diseases. Although its use has implied significant improvements in the prognosis of these diseases, it is not exempt from complications: infectious diseases as one of them. The objective of this consensus was to evaluate, from an infectious viewpoint, the safeness of the most frequently used biological therapies and give recommendations for the prevention of infections in patients treated with these drugs. These recommendations were based on the highest quality evidence available for the selected biologics. The consensus counts of two manuscripts. This first part details the risks of developing infectious complications depending on the type of biological used for a certain pathology. This evaluation included a broad search in MEDLINE and Epistemonikos of systematic reviews and meta-analyzes of controlled clinical trials and casecontrol examining post-treatment infections with anti-TNF alpha, anti-CD20, anti-CD52, CTLA4-Ig and anti-integrins. The research was complemented by a review of: multicentre cohorts of biological users, the MMWR of the CDC, Atlanta, U.S.A., and national registers and scientific societies in which infectious complications derived from the use of biological therapies were mentioned.
Sujet(s)
Anticorps monoclonaux/effets indésirables , Biothérapie/effets indésirables , Maladies transmissibles/induit chimiquement , Consensus , Biothérapie/normes , Chili , Humains , Infections opportunistes/induit chimiquement , Infections opportunistes/prévention et contrôle , Appréciation des risques , Facteurs de risqueRÉSUMÉ
Resumen La incorporación de terapias biológicas ha significado un gran avance en el manejo de diversas patologías de origen autoinmune, neoplásico u otros. Si bien su uso ha implicado mejoras significativas en el pronóstico de estas enfermedades, no está exento de complicaciones, entre estas, las infecciosas. El objetivo de este consenso fue evaluar el perfil de seguridad, desde la mirada infectológica, de las terapias biológicas de uso más frecuente y dar recomendaciones para la prevención de infecciones en pacientes tratados con ellas, basándose en la evidencia de mayor calidad disponible para los biológicos seleccionados. El consenso cuenta de dos manuscritos. Esta primera parte detalla los riesgos de desarrollar complicaciones infecciosas dependiendo del tipo de biológico utilizado para determinada patología. La revisión incluyó búsqueda amplia en MEDLINE y Epistemonikos de revisiones sistemáticas y meta-análisis de estudios clínicos controlados y caso/control que examinaban infecciones posteriores al tratamiento con anti-TNF alfa, anti-CD20, anti-CD52, CTLA4-Ig y anti-integrinas. Esta búsqueda se complementó con revisión de cohortes multicéntricas de usuarios de biológicos, del MMWR del CDC, Atlanta, E.U.A. y de registros nacionales y/o de sociedades científicas en la que se hiciera mención a complicaciones infecciosas derivadas del uso de biológicos.
The use of biological therapies has meant a great improvement in the management of several conditions like autoimmune, neoplastic or others diseases. Although its use has implied significant improvements in the prognosis of these diseases, it is not exempt from complications: infectious diseases as one of them. The objective of this consensus was to evaluate, from an infectious viewpoint, the safeness of the most frequently used biological therapies and give recommendations for the prevention of infections in patients treated with these drugs. These recommendations were based on the highest quality evidence available for the selected biologics. The consensus counts of two manuscripts. This first part details the risks of developing infectious complications depending on the type of biological used for a certain pathology. This evaluation included a broad search in MEDLINE and Epistemonikos of systematic reviews and meta-analyzes of controlled clinical trials and casecontrol examining post-treatment infections with anti-TNF alpha, anti-CD20, anti-CD52, CTLA4-Ig and anti-integrins. The research was complemented by a review of: multicentre cohorts of biological users, the MMWR of the CDC, Atlanta, U.S.A., and national registers and scientific societies in which infectious complications derived from the use of biological therapies were mentioned.
Sujet(s)
Humains , Biothérapie/effets indésirables , Maladies transmissibles/induit chimiquement , Consensus , Anticorps monoclonaux/effets indésirables , Biothérapie/normes , Infections opportunistes/induit chimiquement , Infections opportunistes/prévention et contrôle , Chili , Facteurs de risque , Appréciation des risquesRÉSUMÉ
El uso de inmunosupresores generó una población creciente de pacientes con defectos en el sistema inmune. Creamos un consultorio especializado en la atención infectológica de dichos pacientes. Objetivos: Describir los antecedentes clínicos y la prevalencia de infecciones latentes, evaluar el estado de vacunación, determinar la necesidad de profilaxis antimicrobiana. Describir la frecuencia de aparición infecciones oportunistas (IO). Materiales y métodos: estudio descriptivo, prospectivo de pacientes atendidos en un consultorio que estuvieran bajo tratamiento inmunosupresor (noviembre 2015-enero 2017). Se recolectaron datos demográficos, clínicos y factores de riesgo para IO. Se realizó pesquisa de tuberculosis (TB), serologías para HIV, hepatitis A, B y C, sífilis, toxoplasmosis, Chagas, búsqueda de Strongyloides spp. Se indicaron vacunas de acuerdo con las recomendaciones actuales. Se realizó seguimiento para detección de IO. Resultados: n=197, media de edad 50,7 años (DE 14), mujeres 79,7%. Enfermedades de base: artritis reumatoidea 52%, lupus 12%. Drogas inmunosupresoras: metotrexato 45%, corticoides 16%, biológicos anti-TNF 15%, micofenolato 10%, ciclofosfamida 4%. Se diagnosticaron 49 (25%) infecciones: 15 Chagas, 15 anti-HBc positivo aislado, 7 sífilis, 4 HIV, 4 TB latentes, 2 HBV, 1 HCV, 1 estrongiloidiosis. Se indicó profilaxis antimicrobiana en 27 (14%) pacientes. En todos se intervino indicando o completando los esquemas de vacunación. Se detectaron 7 IO. Conclusiones: En el 39% de los pacientes, la evaluación sistematizada arrojó hallazgos que motivaron intervenciones, ya sea terapéuticas o de monitoreo. En el 100% fue necesaria la prescripción de vacunas. Esto pone en evidencia la importancia de evaluar sistemáticamente en consultorios especializados a estos pacientes
Introduction: The extensive use of immunosuppressive drugs resulted in a growing population of patients with defects in the immune system. We opened an infectious diseases practice focused on the attention of these patients. Our objectives were to describe the clinical history and prevalence of latent infections, evaluate the vaccination status, determine the need for antimicrobial prophylaxis and describe the frequency of opportunistic infections (OI). Methods: We performed a descriptive and prospective study of patients seen at a medical practice who were under immunosuppressive therapy (November 2015-January 2017). Demographic and clinical history, as well as risk factors for OI were collected. Tuberculosis (TB) screening, serologies for HIV, hepatitis A, B and C, syphilis, toxoplasmosis, Chagas and Strongyloides spp. screening were performed. Vaccines were indicated according to current recommendations. Follow-up was performed for IO detection. Results: n=197. Mean age: 50.7 years (SD 14). Female 79.7%. Underlying diseases: rheumatoid arthritis 52%, 12% lupus. Immunosuppressive drugs: methotrexate 45%, corticoids 16%, biological anti-TNF agents 15%, mycophenolate 10%, cyclophosphamide 4%. Forty-nine (25%) infections were diagnosed: 15 Chagas, 15 anti-HBc positive isolated, 7 syphilis, 4 HIV, 4 latent TB, 2 HBV, 1 HCV, 1 strongyloidiosis. Antimicrobial prophylaxis was indicated in 27 (14%) patients. In all cases, vaccination schemes were indicated or completed. Seven IO were detected. Conclusions: In 39% of the patients, the systematized evaluation revealed findings that motivated interventions, either therapeutic or monitoring. In 100% the prescription of vaccines was necessary. These findings highlight the importance of a systematically evaluation of these patients in specialized care centers.
Sujet(s)
Humains , Adulte , Adulte d'âge moyen , Infections opportunistes/prévention et contrôle , Études de cohortes , Vaccination , Système immunitaire/malformations , Système immunitaire/effets des médicaments et des substances chimiques , Anti-infectieux/usage thérapeutiqueRÉSUMÉ
BACKGROUND: Approximately 10% of pancreatic neuroendocrine tumors (NET) are associated with familial syndromes, with the most common type being multiple endocrine neoplasia type 1 (MEN-1). However, the available evidence on how to treat NET comes from studies in sporadic NET. CASE REPORT: Here we report the case of a 51-year-old male patient with a metastatic MEN-1-associated pancreatic NET and hypercalcemia related to primary hyperparathyroidism and tumor-secreted parathyroid-related protein. The patient was treated with everolimus, and showed complete resolution of hypercalcemia and tumor control for 3 years when he presented with pulmonary cryptococcosis and disease progression. CONCLUSION: This case report describes the activity of everolimus in a patient with MEN-1-associated pancreatic NET, its efficacy in treating malignant hypercalcemia associated with NET and the risk of opportunistic infections with prolonged use of this agent.
Sujet(s)
Évérolimus/administration et posologie , Évérolimus/effets indésirables , Néoplasie endocrinienne multiple/traitement médicamenteux , Tumeurs neuroendocrines/traitement médicamenteux , Infections opportunistes/induit chimiquement , Tumeurs du pancréas/traitement médicamenteux , Antinéoplasiques/administration et posologie , Antinéoplasiques/effets indésirables , Humains , Études longitudinales , Mâle , Adulte d'âge moyen , Néoplasie endocrinienne multiple/anatomopathologie , Tumeurs neuroendocrines/anatomopathologie , Infections opportunistes/anatomopathologie , Infections opportunistes/prévention et contrôle , Tumeurs du pancréas/anatomopathologie , Résultat thérapeutiqueRÉSUMÉ
Over 26 years, we found 46 infectious episodes in 350 kidney transplant recipients. Fifteen were urinary tract infections, recurrent in 4 patients. There were 8 cytomegalovirus infections, three of them fatal when intravenous (IV) ganciclovir was not available. Seven patients had a reactivation of tuberculosis (TB) in the pleura, cervical spine, lumbar spine, knee, ankle, skin and peritoneum, respectively, and were all resolved satisfactorily with conventional anti-TB therapy. Three patients transplanted before routine prophylaxis with the use of acyclovir developed an extensive herpes zoster infection in the 1st 6 months after transplantation, which was resolved with the use of oral acyclovir, and 1 had a disseminated herpes simplex infection resolved with the use of IV acyclovir. Three patients transplanted before routine prophylaxis with trimethoprim sulfa developed Pneumocystis carinii pneumonia in the 1st 6 months after transplantation, which was fatal in one of them. In 2 patients, we found a Nocardia infection, confined to the lung, which was cured in one of the cases and systemic and fatal in the other. Two patients transplanted before routine prophylaxis with the use of nystatin developed esophageal candidiasis in the 1st 6 months after transplantation. One patient developed infective endocarditis in a stenotic bicuspid aortic valve and died 10 years later after another incident of infective endocarditis at the prosthetic aortic valve. Two patients developed an extensive condyloma at the penis, perianal region, and perineum owing to human papillomavirus, requiring extensive surgical resection and podophyllin applications. Another patient developed fatal post-transplantation lymphoproliferative disease due to Epstein-Barr virus infection 15 years after transplantation. One patient developed a severe and fatal mucocutaneous leishmaniasis with no response to conventional antimonial therapy. It is interesting to note that despite Chagas disease being endemic in Bolivia, we had no patients with reactivation or transmission through the graft even though many of the patients and donors were serologically positive for Chagas disease.
Sujet(s)
Transplantation rénale/effets indésirables , Infections opportunistes/épidémiologie , Aciclovir/usage thérapeutique , Adolescent , Adulte , Sujet âgé , Bolivie/épidémiologie , Enfant , Infections à cytomégalovirus/prévention et contrôle , Infections à virus Epstein-Barr/prévention et contrôle , Femelle , Ganciclovir/usage thérapeutique , Herpès/prévention et contrôle , Zona/prévention et contrôle , Humains , Mâle , Adulte d'âge moyen , Infections opportunistes/prévention et contrôle , Pneumonie à Pneumocystis/prévention et contrôle , Complications postopératoires/épidémiologie , Complications postopératoires/prévention et contrôle , Études rétrospectives , Tuberculose/prévention et contrôle , Jeune adulteRÉSUMÉ
AIM: Strongyloides stercoralis infection is usually chronic and asymptomatic and may persist undiagnosed for decades. However, in immunocompromised individuals, the infection can cause hyperinfection and dissemination. Therefore, early diagnosis is essential to prevent severe forms of strongyloidiasis. The aims of this study were: (i) to evaluate the frequency of S. stercoralis infection in patients with systemic lupus erythematous (SLE) and (ii) to estimate specific immunoglobulins G (IgG) and E (IgE) production using an enzyme-linked immunosorbent assay (ELISA) method. METHODS: Seventy-five SLE patients treated with prophylactic anthelmintic therapy were evaluated using the spontaneous sedimentation (SS), Baermann-Moraes (BM) and agar plate culture (APC) methods. Serum anti-S. stercoralis IgG and IgE antibodies were measured by ELISA. RESULTS: Using parasitological methods, the frequency of intestinal parasites was 10.7%, whereas the frequency of S. stercoralis infection was 1.3%. The sensitivity of the ELISA to detect anti-S. stercoralis IgG and IgE was 80% and 76.9%, respectively. Both assays presented the same specificity of 96.7%. The frequency of anti-S. stercoralis IgG and IgE was 16% and 28%, respectively. Six patients were positive for both antibodies. CONCLUSIONS: Diagnostic approaches using high-sensitivity parasitological methods and the detection of specific antibodies are essential for the diagnosis of strongyloidiasis in immunocompromised patients. Early detection of infection can alter the course of the disease via appropriate treatment, preventing the occurrence of severe strongyloidiasis.
Sujet(s)
Antihelminthiques antinématodes/administration et posologie , Sujet immunodéprimé , Lupus érythémateux disséminé/immunologie , Infections opportunistes/diagnostic , Infections opportunistes/prévention et contrôle , Strongyloides stercoralis/pathogénicité , Strongyloïdose/diagnostic , Strongyloïdose/prévention et contrôle , Adulte , Animaux , Anticorps antihelminthe/sang , Marqueurs biologiques/sang , Diagnostic précoce , Test ELISA , Femelle , Humains , Immunoglobuline E/sang , Immunoglobuline G/sang , Lupus érythémateux disséminé/diagnostic , Mâle , Adulte d'âge moyen , Infections opportunistes/immunologie , Infections opportunistes/parasitologie , Valeur prédictive des tests , Reproductibilité des résultats , Facteurs de risque , Indice de gravité de la maladie , Strongyloides stercoralis/immunologie , Strongyloïdose/immunologie , Strongyloïdose/parasitologie , Facteurs temps , Résultat thérapeutiqueRÉSUMÉ
Los pacientes portadores de enfermedades reumáticas inflamatorias autoinmunes (AIIRD) tienen mayor riesgo de contraer infecciones, secundario al efecto inmunosupresor de la enfermedad y también por el efecto de los inmunomoduladores utilizados en su tratamiento. Muchas veces los anti-TNF se usan en forma concomitante con metotrexato y corticoides, u otros DMARDs, lo que puede aumentar el riesgo de infección. Entre los efectos adversos graves que se han relacionado con los anti-TNF están las infecciones lo que ha hecho plantear la utilidad de las inmunizaciones para disminuir este riesgo asociado a la enfermedad y a la terapia. Se realizó una revisión de la literatura con el objetivo de analizar los factores que deben ser considerados en el momento de indicar vacunas en estos pacientes.
Patients with autoimmune inflammatory rheumatic diseases (AIIRD) are at higher risk for infections secondary to the immunosuppressive effect of the disease and the effect of the immunomodulators used in their treatment. Anti-TNF are often used concomitantly with methotrexate and corticosteroids, or other DMARDs, which may increase the risk of infection. Among the serious adverse effects that have been associated with anti-TNF are infections that has raised the utility of immunizations to reduce this risk associated with disease and therapy.A review of the literature was carried out with the objective of analyzing the factors that should be considered at the time of indicating vaccines in these patients.
Sujet(s)
Humains , Maladies auto-immunes/complications , Immunosuppresseurs/usage thérapeutique , Rhumatismes/complications , Vaccins/usage thérapeutique , Maladies auto-immunes/traitement médicamenteux , Facteurs immunologiques/usage thérapeutique , Infections opportunistes/prévention et contrôle , Rhumatismes/traitement médicamenteux , VaccinationRÉSUMÉ
BACKGROUND: Despite proven efficacy of prolonged cytomegalovirus (CMV) prophylaxis using valganciclovir 900 mg/day, some centers use 450 mg/day due to reported success and cost savings. This multicenter, retrospective study compared the efficacy and safety of 6 months of low-dose versus high-dose valganciclovir prophylaxis in high-risk, donor-positive/recipient-negative, renal transplant recipients (RTR). METHODS: Two hundred thirty-seven high-risk RTR (low-dose group = valganciclovir 450 mg/day [n = 130]; high-dose group = valganciclovir 900 mg/day [n = s7]) were evaluated for 1-year CMV disease prevalence. Breakthrough CMV, resistant CMV, biopsy-proven acute rejection (BPAR), graft loss, opportunistic infections (OI), new-onset diabetes after transplantation (NODAT), premature valganciclovir discontinuation, renal function and myelosuppression were also assessed. RESULTS: Patient demographics and transplant characteristics were comparable. Induction and maintenance immunosuppression were similar, except for more early steroid withdrawal in the high-dose group. Similar proportions of patients developed CMV disease (14.6% vs 24.3%; P = 0.068); however, controlling CMV risk factor differences through multivariate logistic regression revealed significantly lower CMV disease in the low-dose group (P = 0.02; odds ratio, 0.432, 95% confidence interval, 0.211-0.887). Breakthrough and resistant CMV occurred at similar frequencies. There was no difference in renal function or rates of biopsy-proven acute rejection, graft loss, opportunistic infections, or new-onset diabetes after transplantation. The high-dose group had significantly lower mean white blood cell counts at months 5 and 6; however, premature valganciclovir discontinuation rates were similar. CONCLUSIONS: Low-dose and high-dose valganciclovir regimens provide similar efficacy in preventing CMV disease in high-risk RTR, with a reduced incidence of leukopenia associated with the low-dose regimen and no difference in resistant CMV. Low-dose valganciclovir may provide a significant cost avoidance benefit.
Sujet(s)
Antiviraux/administration et posologie , Infections à cytomégalovirus/prévention et contrôle , Ganciclovir/analogues et dérivés , Sujet immunodéprimé , Transplantation rénale/effets indésirables , Infections opportunistes/prévention et contrôle , Maladie aigüe , Adulte , Antiviraux/effets indésirables , Infections à cytomégalovirus/diagnostic , Infections à cytomégalovirus/épidémiologie , Infections à cytomégalovirus/immunologie , Infections à cytomégalovirus/virologie , Femelle , Ganciclovir/administration et posologie , Ganciclovir/effets indésirables , Rejet du greffon/immunologie , Rejet du greffon/prévention et contrôle , Survie du greffon/effets des médicaments et des substances chimiques , Humains , Estimation de Kaplan-Meier , Modèles logistiques , Mâle , Adulte d'âge moyen , Analyse multifactorielle , Odds ratio , Infections opportunistes/diagnostic , Infections opportunistes/épidémiologie , Infections opportunistes/immunologie , Infections opportunistes/virologie , Prévalence , Études rétrospectives , Facteurs de risque , Facteurs temps , Résultat thérapeutique , États-Unis/épidémiologie , ValganciclovirRÉSUMÉ
Os animais de estimação podem ser fonte de infecções, principalmente para seres humanos imunocomprometidos, em especial, pacientes portadores do vírus HIV. Considerando que o contato com animais pode prover benefícios emocionais, profissionais da área da saúde, em particular médicos e médicos veterinários, devem estar conscientes do papel potencial destes animais na transmissão de doenças de forma a preconizar medidas profiláticas para que esta transmissão não ocorra. As circunstâncias que favorecem a transmissão de doenças a partir dos animais de estimação ainda não são totalmente conhecidas, principalmente na realidade brasileira. Faltam estudos com o objetivo de investigar o risco de doenças de origem zoonótica decorrentes do contato com estes animais, hoje também chamados de animais pet. Ademais, ressente-se da falta de um instrumento devidamente elaborado e validado com a finalidade de captar as informações necessárias para a realização de estudos deste tipo ou mesmo para servir como ferramenta de rastreio de situações de vulnerabilidade de pacientes imunodeprimidos com vistas ao aconselhamento sobre medidas de prevenção. Desta maneira, o objetivo deste estudo é elaborar um instrumento para averiguar a vulnerabilidade de pacientes imunodeprimidos a infecções zoonóticas a partir de animais de estimação. Inicialmente, foram mapeados os animais de estimação mais encontrados no ambiente doméstico e as principais infecções que podem ser transmitidas a partir deles. Selecionaram-se, então, os possíveis mecanismos de transmissão a serem abordados. Dentre as espécies de animais de estimação elencadas, os cães, gatos, aves, répteis e os pequenos roedores foram os selecionados para a confecção deste instrumento. As infecções selecionadas foram: Salmonelose; Criptosporidíase; Giardíase; Dermatofitoses, Esporotricose, Bartonelose; Ancilostomíase; Toxocaríase; Psitacose; Toxoplasmose; Escabiose; Campilobacteriose; Criptococose e Histoplasmose. Considerando as diferentes formas de transmissão de cada infecção foram identificados os possíveis atos e comportamentos no contato com animais de estimação, bem como características destes animais, que poderiam aumentar a probabilidade de transmissão. O instrumento desenvolvido foi composto de uma primeira parte abarcando os critérios de elegibilidade, e de outra envolvendo o escopo principal do instrumento. Como as características de contato e as infecções variam de acordo com a espécie de animal, o instrumento abordou cada um dos cinco grupos de animais separadamente. O instrumento aqui proposto concerne à etapa inicial de um processo de desenvolvimento formal para utilização em futuras pesquisas sobre o papel dos animais de estimação na transmissão de infecções para pacientes imunodeprimidos. Estudos que explorem a confiabilidade e validade do instrumento proposto, assim como sua aceitabilidade, são necessários antes que seu uso seja recomendado
Sujet(s)
Humains , Animaux , Chats , Chiens , Animaux domestiques , VIH (Virus de l'Immunodéficience Humaine) , Patients , Zoonoses , Immunosuppression thérapeutique , Infections opportunistes/prévention et contrôleRÉSUMÉ
Oral mucositis (OM) is one of the side effects of hematopoietic stem cell transplantation (HSCT), resulting in major morbidity. The aim of this study was to determine the cost-effectiveness of the introduction of a specialized oral care program including laser therapy in the care of patients receiving HSCT with regard to morbidity associated with OM. Clinical information was gathered on 167 patients undergoing HSCT and divided according to the presence (n = 91) or absence (n = 76) of laser therapy and oral care. Cost analysis included daily hospital fees, parenteral nutrition (PN) and prescription of opioids. It was observed that the group without laser therapy (group II) showed a higher frequency of severe degrees of OM (relative risk = 16.8, 95% confidence interval -5.8 to 48.9, p < 0.001), with a significant association between this severity and the use of PN (p = 0.001), prescription of opioids (p < 0.001), pain in the oral cavity (p = 0.003) and fever > 37.8°C (p = 0.005). Hospitalization costs in this group were up to 30% higher. The introduction of oral care by a multidisciplinary staff including laser therapy helps reduce morbidity resulting from OM and, consequently, helps minimize hospitalization costs associated with HSCT, even considering therapy costs.
Sujet(s)
Transplantation de cellules souches hématopoïétiques/effets indésirables , Photothérapie de faible intensité , Infections opportunistes/prévention et contrôle , Hygiène buccodentaire/méthodes , Stomatite/thérapie , Conditionnement pour greffe/effets indésirables , Adulte , Sujet âgé , Allogreffes/économie , Antibactériens/administration et posologie , Antibactériens/économie , Antibactériens/usage thérapeutique , Antibioprophylaxie/économie , Antifongiques/administration et posologie , Antifongiques/économie , Antifongiques/usage thérapeutique , Protocoles de polychimiothérapie antinéoplasique/économie , Protocoles de polychimiothérapie antinéoplasique/usage thérapeutique , Brésil , Études cas-témoins , Analyse coût-bénéfice , Dentistes/économie , Coûts des médicaments , Femelle , Transplantation de cellules souches hématopoïétiques/économie , Coûts hospitaliers , Hospitalisation/économie , Humains , Sujet immunodéprimé , Immunosuppresseurs/effets indésirables , Immunosuppresseurs/économie , Immunosuppresseurs/usage thérapeutique , Photothérapie de faible intensité/économie , Photothérapie de faible intensité/méthodes , Mâle , Adulte d'âge moyen , Agonistes myélo-ablatifs/économie , Agonistes myélo-ablatifs/usage thérapeutique , Stupéfiants/économie , Stupéfiants/usage thérapeutique , Infections opportunistes/économie , Infections opportunistes/étiologie , Hygiène buccodentaire/économie , Nutrition parentérale/économie , Équipe soignante , Études rétrospectives , Autosoins/économie , Stomatite/économie , Stomatite/étiologie , Stomatite/prévention et contrôle , Conditionnement pour greffe/économie , Transplantation autologue/économieRÉSUMÉ
AIM: This study evaluated the effect of microwave irradiation as an alternative method for disinfection of different types of denture base acrylic resins. METHODS: Twenty-four samples for each conventional, microwaved and characterized heat-cured acrylic resin were made and subjected to sterilization with ethylene oxide for the groups: 1) irradiated samples; 2) non-irradiated samples; and 3) samples without yeast. Each group was subdivided according to inoculation with C. albicans, C. dubliniensis and C. tropicalis. The samples were inoculated with 100 µL of inoculum of each species of Candida and later placed in an incubator at 37 °C for 1 hr to perform the first adhesion. After this time, each well was supplemented with sterile media and the plate was once again taken to a stove for incubation at 37 °C for 6 hr. The samples were immersed in 100 mL of sterile water and irradiated with microwave at 650 W for 3 min. Control samples were considered as the non-irradiated group. After incubation for 48 hr, irradiated and non-irradiated samples were subjected to a digital colony counter. RESULTS: Control group (non-irradiated) showed microbial growth for resins and the means of ufc/mL were without statistically significant differences. Microwave irradiated samples (experimental group) promoted no viable colonies for all Candida species and types of acrylic resins. The means of ufc/mL were without statistically significant differences. CONCLUSION: Microwave irradiation was an effective method for disinfection of the acrylic resins inoculated with C. albicans, C. dubliniensis and C. tropicalis.
Sujet(s)
Résines acryliques/effets des radiations , Candida/effets des radiations , Désinfection/méthodes , Micro-ondes , Candida/croissance et développement , Candida albicans/croissance et développement , Candida albicans/effets des radiations , Candida tropicalis/croissance et développement , Candida tropicalis/effets des radiations , Candidose/prévention et contrôle , Prothèses dentaires , Contamination de matériel , Oxirane , Température élevée , Humains , Infections opportunistes/prévention et contrôle , Infections dues aux prothèses/prévention et contrôleRÉSUMÉ
The aim of this study was to evaluate the presence of filamentous fungi and yeasts on the external surface of ants at hospitals. From March 2007 to February 2008, 2,899 ants were evaluated in two public hospitals in the city of Fortaleza, Ceará, in northeastern Brazil. The ants were attracted by nontoxic baits, distributed within critical and semicritical hospital areas. The fungi were identified through macro- and micromorphological analysis, biochemical profile, and growth in chromogenic medium. From this study, 5 genera and 13 species of ants were identified, from critical (8% of the collected ants) and semicritical (92%) areas, during the daytime (48%) and nighttime (52%) periods. In the mycological analysis, 75% of the ants were fungi carriers, with the species Tapinoma melanocephalum and species from the genus Pheidole having the most potential as carriers of airborne fungi (75 and 18%, respectively) and yeasts (6 and 1%, respectively). In summary, ants act as carriers of airborne fungi and yeasts, including some pathogenic species.
Sujet(s)
Fourmis/microbiologie , Champignons/isolement et purification , Hôpitaux publics , Vecteurs insectes/microbiologie , Animaux , Brésil , Surveillance de l'environnement , Champignons/classification , Infections opportunistes/microbiologie , Infections opportunistes/prévention et contrôleRÉSUMÉ
Highly active antiretroviral therapy (HAART) has dramatically decreased opportunistic infections (OIs) in human immunodeficiency virus (HIV)-infected patients. However, gastrointestinal disease continues to account for a high proportion of presenting symptoms in these patients. Gastrointestinal symptoms in treated patients who respond to therapy are more likely to the result of drug-induced complications than OI. Endoscopic evaluation of the gastrointestinal tract remains a cornerstone of diagnosis, especially in patients with advanced immunodeficiency, who are at risk for OI. The peripheral blood CD4 lymphocyte count helps to predict the risk of an OI, with the highest risk seen in HIV-infected patients with low CD4 count (< 200 cells/mm(3)). This review provides an update of the role of endoscopy in diagnosing OI in the upper gastrointestinal tract in HIV-infected patients in the era of HAART.
Sujet(s)
Maladies gastro-intestinales/diagnostic , Infections à VIH/complications , Infections opportunistes/diagnostic , Thérapie antirétrovirale hautement active , Biopsie , Numération des lymphocytes CD4 , Candidose/diagnostic , Candidose/épidémiologie , Infections à cytomégalovirus/diagnostic , Infections à cytomégalovirus/épidémiologie , Troubles de la déglutition/étiologie , Troubles de la déglutition/microbiologie , Endoscopie , Maladies de l'oesophage/diagnostic , Maladies de l'oesophage/épidémiologie , Maladies gastro-intestinales/immunologie , Maladies gastro-intestinales/microbiologie , Infections à VIH/traitement médicamenteux , Infections à VIH/immunologie , Herpès/diagnostic , Herpès/anatomopathologie , Humains , Infections opportunistes/prévention et contrôle , Prévalence , Maladies de l'estomac/diagnostic , Maladies de l'estomac/microbiologieRÉSUMÉ
La cuarta edición del libro Tratamiento de las enfermedades infecciosas 2009-2010, cuyo contenido está basado en consultas de reconocidos expertos en el campo de la infectología, pediatría y microbiología clínica, quienes revisaron y actualizaron ediciones anteriores de la publicación, incorporando la evidencia más sólida disponible en el momento actual. Con los aportes de todos ellos, se elaboró un instrumento sencillo, integral y completo, de fácil consulta, para tomar decisiones sobre el trata-miento de enfermedades infecciosas. La prescripción de antimicrobianos se realiza generalmente de manera empírica, y es necesario disponer de herramientas adaptadas a la Región, respecto a la ecología bacte-riana, patrones de resistencias y la disponibilidad de antibióticos en los diferentes niveles de atención. La 4ª edición revisa y actualiza los tratamientos de todas las enfermedades infecciosas y simplifica las pautas para facilitar el cumplimiento de las mismas por parte de los pacientes. Además, incorpora las nuevas pautas de tratamiento VIH-SIDA pediátrico y adulto, e infecciones oportunistas en pacientes con SIDA, siguien-do las recomendaciones actuales de la OPS/OMS.
Sujet(s)
Humains , Mâle , Femelle , Enfant , Anti-infectieux , Antibactériens/usage thérapeutique , Prévention des infections/normes , Maladies transmissibles , Infections opportunistes/prévention et contrôle , Résistance aux substancesRÉSUMÉ
Las lesiones bucales, que pueden ser, en muchas ocasiones, las primeras manifestaciones clínicas detectables para el diagnóstico del VIH; en otros casos, la aparición de alguna de ellas en las distintas etapas de la infección, puede marcar una tendencia al progreso a la etapa SIDA. Establecer el impacto del entrenamiento sobre salud bucal de las madres VIH/SIDA, que acuden al Hospital Universitario de Caracas (HUC) en la prevención de infecciones oportunistas y del progreso de la enfermedad en ella y su hijo, basado en la experiencia de un programa educativo en salud bucal dirigido a ellas. Se dictaron charlas interactivas y se elaboró un instrumento de dos partes; a) una entrevista a las madres para obtener información sobre variables sociodemográficas, métodos de higiene bucal, alimentación y hábitos, b) un examen bucal. Para el 2005, se habían dictado charlas interactivas a 200 madres VIH+, de las cuales solo 123 respondieron a las sugerencias propuestas, 43 asistieron por razones de emergencia y no por las expuestas en las charlas y 34 no volvieron. Dado que la respuesta por parte de las madres que participaron en el programa, fue insuficiente, puede decirse que el impacto del mismo en la prevención de infecciones oportunistas y del progreso del VIH a SIDA en ella y su hijo, no puede establecerse con precisión; pero considerando la importancia que este entrenamiento puede tener en el control de la infección, se sugiere la reevaluación de este programa
Quite often oral lesions can be the first clinically detectable manifestations for the diagnosis of HIV; on the other hand, the incidence of any of them during the stages of the infection, can determine a tendency to the progression towards AIDS. To establish the impact of training HIV(+) mothers, treated at the Hospital Universitario de Caracas (HUC), about oral heath and the prevention of the incidence of opportunist infections as well as the progression of the disease. Participatory sessions were organized and an instrument consisting of two parts, a personal interview and an oral exam, was made. By 2005: 200 HIV(+) mothers participated, but only 123 responded to the proposed suggestions, 43 returned for emergency reasons and not for the ones proposed in the sessions and 34 were unavailable for follow-ups. Due to the insufficient response on the part of the participating mothers, there is not enough ground to state that the impact of the program in the prevention of opportunist infections as well as the progression of the disease in them and their children has been established. This suggest the need of a reevaluation of this training program